嵌合抗原受体T细胞治疗滤泡淋巴瘤的研究进展  

Progress of chimeric antigen receptor T-cell for treatment of follicular lymphoma

作　　者：宁海玲 张秀莲[1] Ning Hailing;Zhang Xiulian(Department of Hematology,the First Hospital of Shanxi Medical University,Taiyuan 030001,China)

机构地区：[1]山西医科大学第一医院血液科,太原030001

出　　处：《肿瘤研究与临床》2019年第10期717-720,共4页Cancer Research and Clinic

摘　　要：滤泡淋巴瘤(FL)通常发病隐匿,病程表现和预后差异很大。近年来随着抗CD20单克隆抗体与标准化疗方法的结合以及免疫调节剂、造血干细胞移植的应用,FL患者的生存率有了很大提高,但仍被认为是一种无法治愈的疾病。新近研究表明嵌合抗原受体T细胞(CAR-T)治疗可提高FL患者生存率,改善预后。文章将从CAR-T治疗FL的机制、临床研究进展、不良反应及局限性等方面进行阐述。Follicular lymphoma(FL)is usually occult,with a wide range of disease manifestations and prognosis.In recent years,with the combination of anti-CD20 monoclonal antibody and standard chemotherapy methods,as well as the use of immunomodulators and hematopoietic stem cell transplantation,the survival rate of FL patients has been greatly improved,but it is still considered to be an incurable disease.Recent studies have shown that the chimeric antigen receptor T-cell(CAR-T)therapy can improve the survival rate and the prognosis of FL patients.The article will elaborate on the mechanism,clinical research progress,adverse reactions and limitations of CAR-T in the treatment of FL.

关 键 词：淋巴瘤 滤泡型 嵌合抗原受体T细胞 CD19 抗CD20单克隆抗体 

分 类 号：R73[医药卫生—肿瘤]